Neoadjuvant treatments in gastrointestinal oncology;Les traitements néo-adjuvants en cancérologie digestive

Journal de Chirurgie

Volumn 144, Issue 5, 2007, Pages 393-397

  Rebischung, C ^a   Laramas, M ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Colorectal cancer; Esophageal cancer; Gastric cancer; Liver metastasis; Neoadjuvant chemoradiotherapy; Neoadjuvant chemotherapy

Indexed keywords

EID: 37249086087     PISSN: 00217697     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-7697(07)73993-5     Document Type: Short Survey

References (32)

1. Remontet L, Esteve J, Bouvier AM et al. Incidence et mortalité des cancers en France sur la période 1978-2000. Rev Epidemiol Santé Publique 2003;51:3-30
2. MacDonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;10:725-730.
3. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. The MAGIC trial. N Engl J Med 2006;355:11-20.
4. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin and fluorouracil versus fluorouracil, doxorubicin and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-267.
5. Ychou M, Pignon P, Lasser P et al. Phase III preliminary results of preoperative fluorouracil and cisplatin versus surgery alone in adenocarcinoma of stomach and lower esophagus: FNLCC 94012-FFCD9703 trial. Proceedings of the ASCO Annual Meeting 2006; abstract 4026.
6. Medical Research Council Oesophageal Cancer Working party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-1733.
7. Bosset JF, Gignoux M, Triboulet JP et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-167.
8. Recommandations pour la pratique clinique : prise en charge thérapeutique des métastases hépatiques des cancers colorectaux. Gastroenterol Clin Biol 2003;27:B14-5, B63-79.
9. Portier G, Elias D, Bouché O et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases. J Clin Oncol 2006;24:4976-4982.
10. Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-520.
11. Adam R, Avisar E, Ariche A et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal cancer. Ann Surg Oncol 2001;8:347-353.
12. Giacchetti S, Itzhaki M, Gruia G et al. Long term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-669.
13. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. A model to predict long term survival. Ann Surg 2004;4:644-658.
14. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
15. Falcone A, Masi G, Allegrini G et al. Biweekly chemotherapy with Oxaliplatine, Irinotecan, infusional Fluorouracil and Leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002;20: 4006-4014.
16. Ychou M, Conroy T, Seitz JF et al. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 2003;14: 481-489.
17. Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg 2006;93: 872-878.
18. Falcone A, Masi G, Brunetti I et al. The triplet combination of irinotecan, oxaliplatin and 5FU/LV (FOLFOXIRI) vs the doublet of irinotecan and 5FU/LV (FOLFIRI) as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized phase III trial. Proceedings of the ASCO Annual Meeting 2006, abstract 3513.
19. Maindrault-Goebel F, Lledo G, Chibaudel B et al. A. OPTIMOX 2, a large randomised phase II study of maintenance therapy or chemotherapy-free intervals after FOLFOX in patients with metastatic colorectal cancer. Proceedings of the ASCO Annual Meeting 2006, abstract 3504.
20. Iyer L, Das S, Janisch L et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002;2:43-47.
21. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus Irinotecan and Leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
22. Hochster H, Hart L, Ramanathan R et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. Proceedings of the ASCO Annual Meeting 2006, abstract 3510.
23. Díaz Rubio E, Tabernero J, Van Cutsem E, Cervantes A. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/ folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. Proceedings of the ASCO Annual Meeting 2005, abstract 3535.
24. Rougier P, Raoul JL, Van Laethem JL et al. Cetuximab-Folfiri as first-treatment for metastatic colorectal cancer. Proceedings of the ASCO Annual Meeting 2004, abstract 3513.
25. André T, Tabernero J, Van Cutsem E et al. Phase II study with Cetuximab plus FOLFOX-4 in first-line setting for epidermal growth factor receptor (EGFR) expressing colorectal cancer. Proceedings of the ASCO-GI Annual Meeting 2007, abstract 334.
26. Ducreux M, Ychou M, Laplanche A et al. Hepatic arterial Oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases : a trial of the gastrointestinal group of the Federation National des Centres de Lutte Contre le Cancer. J Clin Oncol 2005;23:4815-4817.
27. Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065-2072.
28. Rubbia-Brandt L, Giostra E, Brezault C et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 2007;18:299-304.
29. Benoist S, Brouquet A, Penna C et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol, 2006;24:3939-3945.
30. Kapiteijn E, Marijnen CAM, Nagtegaal I et al. Preoperative radiotherapy combined with total mesorectum excision for resectable rectal cancer. New Engl J Med 2001;345:638-646.
31. Bosset JF, Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-1123.
32. Gerard JP, Conroy T, Bonnetain F et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620-4625.